SPDR S&P Biotech ETF (NYSE:XBI) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the “index”), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (“S&P TMI”).

finviz dynamic chart for  XBI

SPDR S&P Biotech ETF seeks to provide investment results that correspond to the total return performance of the S&P Biotechnology Select Industry Index.

Fund Overview

  • Net Assets 7.36 Billions
  • 1-Year Daily Total Return 12.17%
  • Yield 0.23%
  • Annual Expense Ratio 0.35%

This ETF has modified equal-weighted index which provides exposure to large, mid, and small-cap stocks in the biotech ecosystem. XBI’s equal weight structure gives investors “unconcentrated exposure” to 172 biotech companies. This includes the smaller, more risky drug manufacturers who can see their share price rise or fall dramatically depending on approvals (or rejections) from the FDA.

Top 10 Holdings (8.60% of Total Assets)

NameSymbol% Assets
Intellia Therapeutics IncNTLA1.18%
Editas Medicine IncEDIT0.94%
Anavex Life Sciences CorpAVXL0.92%
Beam Therapeutics IncBEAM0.90%
MannKind CorpMNKD0.84%
Translate Bio IncTBIO0.80%
Macrogenics IncMGNX0.79%
Ocugen IncOCGN0.79%
Seres Therapeutics IncMCRB0.72%
Twist Bioscience CorpTWST0.72%

6 Comments to “Best BioTech ETF (XBI)”

Post Comment